Patents by Inventor Joseph A. Beavo
Joseph A. Beavo has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7842478Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: GrantFiled: August 9, 2006Date of Patent: November 30, 2010Assignee: The Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, J. Kelley Bentley, Harry Charbonneau, William K. Sonnenburg
-
Patent number: 7598067Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.Type: GrantFiled: June 1, 2006Date of Patent: October 6, 2009Assignees: University of Bern, University of WashingtonInventors: Joseph A. Beavo, Thomas Seebeck, Scott Haydn Soderling, Ana Rascon, Roya Zoraghi, Stefan Kunz, Kewei Gong, Natalie Glavas
-
Publication number: 20070116705Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.Type: ApplicationFiled: June 1, 2006Publication date: May 24, 2007Applicant: University of WashingtonInventors: Joseph Beavo, Thomas Seebeck, Scott Soderling, Ana Rascon, Roya Zoraghi, Stefan Kunz, Kewei Gong, Natalie Glavas
-
Patent number: 7179614Abstract: The present invention relates to novel methods of signal transduction in cells. In particular, the invention relates to signal transduction via a class of enzymes known as phosphodiesterase enzymes or PDEs. The invention also relates to a class of signaling molecules known as G-coupled protein receptors (GCPRs) and G-proteins. The invention provides novel methods to screen for and identify G-proteins and other compounds which modulate signaling by these two classes of proteins. In particular, the relates to novel assays which identify compounds that modulate (e.g., enhance or inhibit) binding between a PDE polypeptide and an effector activation domain of a G-protein.Type: GrantFiled: September 14, 2001Date of Patent: February 20, 2007Assignees: Mount Sinai School of Medicine, University of WashingtonInventors: Robert Margolskee, Joseph Beavo
-
Publication number: 20060275871Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: ApplicationFiled: August 9, 2006Publication date: December 7, 2006Applicant: THE BOARD OF REGENTS OF THE UNIVERSITY OF WASHINGTONInventors: Joseph Beavo, J. Bentley, Harry Charbonneau, William Sonnenburg
-
Patent number: 7138259Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.Type: GrantFiled: September 12, 2001Date of Patent: November 21, 2006Assignees: University of Washington, University of BernInventors: Joseph A. Beavo, Thomas Seebeck, Scott Haydn Soderling, Ana Rascon, Roya Zoraghi, Stefan Kunz, Kewei Gong, Natalie Glavas
-
Patent number: 7122363Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: GrantFiled: October 30, 2003Date of Patent: October 17, 2006Assignee: The Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Kelley J. Bentley, Harry Charbonneau, William K. Sonnenburg
-
Publication number: 20060222647Abstract: The present invention provides agents such as agonists, antibodies, antagonists or inhibitors to modulate the activity of PDE5 proteins. These compositions and methods are useful for the diagnosis or treatment of conditions associated with the presence, the deficiency, altered levels, or altered activity of PDE5 proteins.Type: ApplicationFiled: January 28, 2003Publication date: October 5, 2006Inventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Linda McAllister-Lucas, Kate Loughney, William Sonnenburg, Melissa Thomas, Sergei Rybalkin
-
Publication number: 20060216809Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: December 21, 2005Publication date: September 28, 2006Applicants: ICOS CORPORATIONInventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Kate Loughney, Linda McAllister-Lucas, William Sonnenburg, Melissa Thomas
-
Publication number: 20050196833Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding. cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: January 28, 2003Publication date: September 8, 2005Inventors: Joseph Beavo, Jackie Corbin, Kenneth Ferguson, Sharron Francis, Ann Kadlecek, Linda McAllister-Lucas, Kate Loughney, William Sonnenburg, Melissa Thomas
-
Publication number: 20050058998Abstract: The present invention provides isolated full-length nucleic acid molecules encoding the novel PDE protein of the invention, and methods for uses thereof. The nucleic acid molecules of the invention also include peptide nucleic acids (PNA), and antisense molecules that react with the nucleic acid molecules of the invention. The invention also relates to agonists, antibodies, antagonists or inhibitors of the activity of novel PDE proteins. These compositions are useful for the diagnosis, prevention or treatment of conditions associated with the presence or the deficiency of novel PDE proteins.Type: ApplicationFiled: September 12, 2001Publication date: March 17, 2005Inventors: Joseph Beavo, Thomas Seebeck, Scott Soderling, Ana Rascon, Roya Zoraghi, Stefan Kunz, Kewen Gong, Natalie Glavas
-
Publication number: 20040126866Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: ApplicationFiled: October 30, 2003Publication date: July 1, 2004Inventors: Joseph A. Beavo, J. Kelley Bentley, Harry Charbonneau, William K. Sonnenburg
-
Publication number: 20040063148Abstract: The present invention relates to novel methods of signal transduction in cells. In particular, the invention relates to signal transduction via a class of enzymes known as phosphodiesterase enzymes or PDEs. The invention also relates to a class of signaling molecules known as G-coupled protein receptors (GCPRs) and G-proteins. The invention provides novel methods to screen for and identify G-proteins and other compounds which modulate signaling by these two classes of proteins. In particular, the relates to novel assays which identify compounds that modulate (e.g., enhance or inhibit) binding between a PDE polypeptide and an effector activation domain of a G-protein.Type: ApplicationFiled: March 12, 2003Publication date: April 1, 2004Inventors: Robert Margolskee, Joseph Beavo
-
Patent number: 6642040Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: GrantFiled: June 18, 2001Date of Patent: November 4, 2003Assignee: The Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Kelley J. Bentley, Harry Charbonneau, William K. Sonnenburg
-
Publication number: 20030054992Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: ApplicationFiled: April 3, 2002Publication date: March 20, 2003Applicant: ICOS CorporationInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Publication number: 20020151024Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca2+/calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: ApplicationFiled: June 18, 2001Publication date: October 17, 2002Applicant: The Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, J. Kelley Bentley, Harry Charbonneau, William K. Sonnenburg
-
Patent number: 6037119Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: March 14, 2000Assignee: Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 6015677Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca.sup.2+ /calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: GrantFiled: August 25, 1998Date of Patent: January 18, 2000Assignee: The Board of Regents of the University of WashingtonInventors: Joseph A. Beavo, Kelley J. Bentley, Harry Charbonneau, William K. Sonnenburg
-
Patent number: 5955583Abstract: The present invention provides novel purified and isolated nucleotide sequences encoding the cGMP-binding, cGMP-specific phosphodiesterase designated cGB-PDE. Antibodies to the cGMP-binding, cGMP-stimulated phosphodiesterase are disclosed. Also provided by the invention are methods and materials for the recombinant production of cGB-PDE polypeptide products and methods for identifying compounds which modulate the enzymatic activity of cGB-PDE polypeptides.Type: GrantFiled: June 5, 1995Date of Patent: September 21, 1999Assignees: ICOS Corporation, Board of Regents of the University of Washington, Vanderbilt UniversityInventors: Joseph A. Beavo, Jackie D. Corbin, Kenneth M. Ferguson, Sharron H. Francis, Ann Kadlecek, Kate Loughney, Linda M. McAllister-Lucas, William K. Sonnenburg, Melissa K. Thomas
-
Patent number: 5800987Abstract: The present invention relates to novel purified and isolated nucleotide sequences encoding mammalian Ca.sup.2+ /calmodulin stimulated phosphodiesterases (CaM-PDEs) and cyclic-GMP-stimulated phosphodiesterases (cGS-PDEs). Also provided are the corresponding recombinant expression products of said nucleotide sequences, immunological reagents specifically reactive therewith, and procedures for identifying compounds which modulate the enzymatic activity of such expression products.Type: GrantFiled: May 31, 1995Date of Patent: September 1, 1998Assignee: The Board of Regents of The University of WashingtonInventors: Joseph A. Beavo, J. Kelley Bentley, Harry Charbonneau, William K. Sonnenburg